Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Ross S. Greenberg; Jake A. Ruddy; Brian J. Boyarsky; William A. Werbel; Jacqueline M. Garonzik-Wang; Dorry L. Segev; Philip H. Imus

doi:10.1186/s12885-021-09097-5

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Ross S. Greenberg, Jake A. Ruddy, Brian J. Boyarsky, William A. Werbel, Jacqueline M. Garonzik-Wang, Dorry L. Segev, Philip H. Imus

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021. Results: Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted. Conclusions: Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.

Original language	English (US)
Article number	1354
Journal	BMC cancer
Volume	21
Issue number	1
DOIs	https://doi.org/10.1186/s12885-021-09097-5
State	Published - Dec 2021

Keywords

Antibody
COVID-19
Multiple myeloma
SARS-CoV-2
mRNA vaccination

ASJC Scopus subject areas

Oncology
Genetics
Cancer Research

Access to Document

10.1186/s12885-021-09097-5

Cite this

@article{fb243ae1918e4100a1f4b3c79968bb1d,

title = "Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma",

abstract = "Background: Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021. Results: Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted. Conclusions: Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.",

keywords = "Antibody, COVID-19, Multiple myeloma, SARS-CoV-2, mRNA vaccination",

author = "Greenberg, {Ross S.} and Ruddy, {Jake A.} and Boyarsky, {Brian J.} and Werbel, {William A.} and Garonzik-Wang, {Jacqueline M.} and Segev, {Dorry L.} and Imus, {Philip H.}",

note = "Funding Information: This research was made possible with generous support of the Ben-Dov family. This work was supported by grant number F32DK124941 (Boyarsky) and K23DK115908 (Garonzik-Wang) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and K24AI144954 (Segev) from National Institute of Allergy and Infectious Diseases (NIAID). Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s12885-021-09097-5",

language = "English (US)",

volume = "21",

journal = "BMC cancer",

issn = "1471-2407",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

AU - Greenberg, Ross S.

AU - Ruddy, Jake A.

AU - Boyarsky, Brian J.

AU - Werbel, William A.

AU - Garonzik-Wang, Jacqueline M.

AU - Segev, Dorry L.

AU - Imus, Philip H.

N1 - Funding Information: This research was made possible with generous support of the Ben-Dov family. This work was supported by grant number F32DK124941 (Boyarsky) and K23DK115908 (Garonzik-Wang) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and K24AI144954 (Segev) from National Institute of Allergy and Infectious Diseases (NIAID). Publisher Copyright: © 2021, The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - Background: Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021. Results: Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted. Conclusions: Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.

AB - Background: Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021. Results: Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted. Conclusions: Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.

KW - Antibody

KW - COVID-19

KW - Multiple myeloma

KW - SARS-CoV-2

KW - mRNA vaccination

UR - http://www.scopus.com/inward/record.url?scp=85121747268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121747268&partnerID=8YFLogxK

U2 - 10.1186/s12885-021-09097-5

DO - 10.1186/s12885-021-09097-5

M3 - Article

C2 - 34961488

AN - SCOPUS:85121747268

SN - 1471-2407

VL - 21

JO - BMC cancer

JF - BMC cancer

IS - 1

M1 - 1354

ER -

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this